MacroGenics to Receive $24.5M Milestone Payment from Sanofi for TZIELD® Approval
MGNX has more than doubled off its 52-week low of $1.185 on elevated volume (2.0× avg).
Summary
MacroGenics will receive a $24.5 million regulatory milestone payment from Sanofi following the FDA's expanded approval of TZIELD® for children with stage 3 type 1 diabetes. This non-dilutive cash inflow is substantial, representing over 8% of MacroGenics' current market capitalization. It further strengthens the company's financial position, building on recent non-dilutive funding that extended its cash runway through 2028. MacroGenics remains eligible for up to $305 million in additional milestone payments and royalties on global net sales.
At the time of this announcement, MGNX was trading at $4.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $291.1M. The 52-week trading range was $1.19 to $4.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.